Delivering unmatched convenience, efficiency, and expertise-all in one centralized hub for access control, security, and loading dock solutions.
Read More
Motivation Mindset Labs today announced promising results from its innovative 4-Week Virtual Nordic Walking Challenge, a research-based program created to support individuals living with Parkinson's disease in improving their walking consistency, mood, and overall motivation. The program combined scenic virtual routes, personalized goal tracking, and daily motivational text messages to simulate memorable adventures.
Read MoreJaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®
A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals
Read More
Led by Menlo Ventures, with participation Sequoia Capital, and Cyberstarts, Zafran is doubling its valuation since the last round to advance the mission of stopping vulnerability exploitation everywhere
Read More
Black Book Research launches US Hospital Cyber Resilience 2026 - Volume 2: Identity, Insurance, and Incident Readiness, a free, vendor-neutral guide for hospital leaders navigating AI-driven cyber incidents and upstream vendor risk.
Read MoreLaing's appointment to support industrywide adoption of the IEEE 802.16t ("dot16") protocol, pioneered by Ondas Networks and selected by AAR as the upgrade path for network modernization and mission-critical rail communications in North America
Veteran Class I engineering leader with prior executive roles at Canadian Pacific Railway and Canadian National joins Ondas Networks Board
Laing was the 2023 RT&S Engineer of the Year, currently serves on AREMA's Board of Governors
Read More
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-
- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® -
Read More
New Analysis Reveals Real Hourly Pay is Falling Double-Digits Behind Inflation in Major Metros, Fueling a Localized Affordability Crisis and the Most Geographically Uneven Holiday Earnings Season Since the Pandemic
Read More
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases.
Read More
Highlights
(Unless otherwise noted, all financial amounts in this news release are expressed in U.S. dollars. IBC is reporting the performance of "continuing operations" at its Copper Alloy division, "discontinued operations" at its Massachusetts facility, and a combination of continuing and discontinued operations.1
The operating loss from continuing operations in the quarter improved from $226,000 to $67,000.
On a consolidated basis, Adjusted EBITDA for the quarter of ($55,000) compared favorably to adjusted EBITDA1 of ($449,000) in the prior year quarter. IBC recorded a loss of $702,000, which compared favorably to a loss in the prior-year quarter of $1.2 million.
Sales of $4.2 million for the quarter ended September 30, 2025 declined by 14.8% year-over-year (YOY).